Non-viral delivery of nuclear factor-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis

Gut

Volumn 56, Issue 4, 2007, Pages 524-533

  De Vry, Christopher G ^b   Prasad, Srinivasa ^b   Komuves, Laszlo ^b   Lorenzana, Carlos ^b   Parham, Christi ^b   Le, Tina ^b   Adda, Sarvesh ^b   Hoffman, Jennifer ^b   Kahoud, Nicole ^b   Garlapati, Radhika ^b   Shyamsundar, Radha ^b   Mai, Kim ^b   Zhang, Jie ^b   Muchamuel, Tony ^b   Dajee, Maya ^b   Schryver, Brian ^b   McEvoy, Leslie M ^b   Ehrhardt, Rolf O ^a,b  

^a InterMune Inc   (United States)

^b Department of Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; DEXTRAN; DRUG VEHICLE; FLUORESCENT DYE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEAR FACTOR KAPPA B DECOY; OXAZOLONE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HOMEOSTASIS; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HOMEOSTASIS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; OXAZOLONE; TRINITROBENZENESULFONIC ACID;

EID: 34147207287     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.096487     Document Type: Article

References (54)

1. Bouma G, Straber W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
4. Hibi T, Inoue N, Ogata H, et al. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003;38(Suppl 15):36-42.
5. Podolsky DK. The future of IBD treatment. J Gastroenterol 2003;38(Suppl 15):63-6.
6. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
7. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
8. Neurath MF, Puss I, Schurmann G, et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 1998;859:149-59.
9. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998;42:477-84.
10. Spiik AK, Ridderstad A, Axelsson LG, et al. Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 antisense oligonucleotides. Int J Colorectal Dis 2002;17:223-32.
11. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003;124:1265-70.
12. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
13. Wrighton CJ, Hofer-Warbinek R, Moll T, et al. Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B. J Exp Med 1996;183:1013-22.
14. Murano M, Maemura K, Hirata I, et al. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 2000;120:51-8.
15. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
16. Yan F, Polk DB. Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. J Biol Chem 1999;274:36631-6.
17. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116:602-9.
18. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
19. Alkalay I, Yaron A, Hatzubai A, et al. Stimulation- dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1995;92:10599-603.
20. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003;81:235-45.
21. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
22. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
23. Hollenbach E, Neumann M, Vieth M, et al. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004;18:1550-2.
24. Segain JP, Raingeard de la Bletiere D, Sauzeau V, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 2003;124:1180-7.
25. Pimentel-Muinos FX, Mazana J, Fresno M. Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha. Eur J Immunol 1995;25:179-86.
26. Ardite E, Panes J, Miranda M, et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 1998;124:431-3.
27. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
28. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
29. Dzau VJ, Mann MJ, Morishita R, et al. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996;93:11421-5.
30. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-9.
31. Nakamura H, Morishita R, Kaneda Y. Molecular therapy via transcriptional regulation with double-stranded oligodeoxynudeotides as decoys. In Vivo 2002;16:45-8.
32. Finco TS, Baldwin AS. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995;3:263-72.
33. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58:227-9.
34. Cao CC, Ding XQ, Ou ZL, et al. In vivo transfection of NF-kappaB decoy oligodeoxynudeotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 2004;65:834-45.
35. Desmet C, Gosset P, Pajak B, et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 2004;173:5766-75.
36. Nakamura H, Aoki M, Tamai K, et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynudeotides in NC/ Nga atopic mouse model. Gene Ther 2002;9:1221-9.
37. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynudeotides as a gene therapy. Arthritis Rheum 1999;42:2532-42.
38. Fichtner-Feígl S, Fuss U, Preiss JC, et al. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappaB decoy oligonucleotides. J Clin Invest 2005;115:3057-71.
39. Fuss U, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-88.
40. Heller F, Fuss U, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38.
41. Myers KJ, Murthy S, Flanigan A, et al. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 2003;304:411-24.
42. Fort MM, Mozaffarian A, Stover AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005;174:6416-23.
43. Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-9.
44. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003;4:721-32.
45. Dajee M, Muchamuel T, Schryver B, et al. Blockade of experimental atopic dermatitis via topical NF-kB decoy oligonucleotide. J Invest Dermatol 2006;126:1792-803.
46. Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997;280:988-1000.
47. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53:1646-51.
48. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
49. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
50. Wright NA, Poulsom R, Stamp G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993;104:12-20.
51. Manning AM, Bell FP, Rosenbloom CL, et al. NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J Inflamm 1995;45:283-96.
52. Hilliard BA, Mason N, Xu L, et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002;110:843-50.
53. Sanjabi S, Hoffmann A, Liou HC, et al. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA 2000;97:12705-10.
54. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5:800-8.